We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+16.34%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.59B
AUM Growth
+$94.4M
(+3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-5.13%
Top 10 Holdings %
Top 10 Hldgs %
44.17%
Holding
70
New
30
Increased
7
Reduced
17
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maravai LifeSciences
MRVI
|
+$87.3M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$79.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$72.1M |
| 4 |
HOLX
Hologic
HOLX
|
+$71.8M |
| 5 |
McKesson
MCK
|
+$70.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$113M |
| 2 |
Zimmer Biomet
ZBH
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$107M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$93.1M |
| 5 |
Medtronic
MDT
|
+$87.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.87% |
| 2 | Real Estate | 3.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
51
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.75M | 0.07% |
+55,150
| New | +$1.45M |
|
52
Incyte
INCY
$24.4B
| $1.7M | 0.07% |
19,530
-3,050
| -14% | -$264K |
|
|
FPRX
53
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.48M | 0.06% |
+86,930
| New | +$1.09M |
|
54
Anika Therapeutics
ANIK
$287M
| $920K | 0.04% |
+20,320
| New | +$771K |
|
55
Align Technology
ALGN
$12.3B
| – | – |
-14,680
| Closed | -$4.81M |
|
56
Amgen
AMGN
$222B
| – | – |
-233,740
| Closed | -$59.4M |
|
57
American Well
AMWL
$230M
| – | – |
-12,500
| Closed | -$7.41M |
|
58
CALL
Arcturus Therapeutics
ARCT
$211M
| – | – |
-200,000
| Closed | -$8.58M |
|
|
59
Arcturus Therapeutics
ARCT
$211M
| – | – |
-1,594,452
| Closed | -$68.4M |
|
60
Assembly Biosciences
ASMB
$529M
| – | – |
-43,291
| Closed | -$8.54M |
|
|
LONA
61
LeonaBio Inc
LONA
$72.1M
| – | – |
-21,750
| Closed | -$4.01M |
|
62
Danaher
DHR
$144B
| – | – |
-163,109
| Closed | -$31.1M |
|
63
Dyne Therapeutics
DYN
$4.9B
| – | – |
-120,000
| Closed | -$2.42M |
|
64
Pediatrix Medical
MD
$2.2B
| – | – |
-3,234,280
| Closed | -$52.7M |
|
65
Outset Medical
OM
$90.8M
| – | – |
-2,333
| Closed | -$1.75M |
|
|
66
Regeneron Pharmaceuticals
REGN
$80.8B
| – | – |
-190,310
| Closed | -$107M |
|
67
Stryker
SYK
$130B
| – | – |
-118,550
| Closed | -$24.7M |
|
68
Zymeworks
ZYME
$1.67B
| – | – |
-345,550
| Closed | -$16.1M |
|
|
ARNA
69
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-310,000
| Closed | -$23.2M |
|
|
ARNA
70
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-578,030
| Closed | -$43.2M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2020 Portfolio in Review
As of Q4 2020, HealthCor Management held 70 positions worth $2.59B, up 3.8% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
HealthCor Management withdrew a net $133M in Q4 2020, closing 16 positions and reducing 17 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $107M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Real Estate.
Against the trend, HealthCor Management opened a new position in Maravai LifeSciences worth $87.9M.
- HealthCor Management's largest Q4 2020 buy was Maravai LifeSciences: 3,134,712 shares worth $87.9M.
- HealthCor Management added most to Bristol-Myers Squibb in Q4 2020, an estimated $72.1M increase.
- HealthCor Management's biggest Q4 2020 reduction was UnitedHealth, cutting an estimated $113M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q4 2020, selling an estimated $107M.
- HealthCor Management's ten largest holdings make up 44% of its $2.59B portfolio in Q4 2020.
- HealthCor Management opened 30 new positions and closed 16 in Q4 2020.
- HealthCor Management's portfolio value rose 3.8% quarter-over-quarter to $2.59B.
Based on HealthCor Management's 13F filing for Q4 2020, filed 16 Feb 2021.